Gallium citrate Ga-67
Identification
- Summary
Gallium citrate Ga-67 is a radiopharmaceutical agent used in the detection of the presence and extent of Hodgkin's disease, lymphoma, and bronchogenic carcinoma, as well as some acute inflammatory lesions.
- Brand Names
- Gallium
- Generic Name
- Gallium citrate Ga-67
- DrugBank Accession Number
- DB06784
- Background
Gallium citrate Ga 67 is the citrate salt of the radioisotope gallium Ga 67. Although the mechanism is unknown, gallium Ga 67 concentrates in lysosomes and is bound to a soluble intracellular protein in certain viable primary and metastatic tumors and focal sites of inflammation, allowing scintigraphic localization. Ga-67 scintigraphy (GS) cannot differentiate between tumor and acute inflammation. [NCI Thesaurus]
- Type
- Small Molecule
- Groups
- Approved
- Structure
- Weight
- Average: 256.0279
Monoisotopic: 255.931732429 - Chemical Formula
- C6H5GaO7
- Synonyms
- Gallium (67 Ga) citrate
- Gallium citrate Ga 67
- Gallium citrate Ga-67
- Gallium-67 Citrate
Pharmacology
- Indication
Gallium Citrate Ga 67 Injection may be useful to demonstrate the presence and extent of Hodgkin's disease, lymphoma, and bronchogenic carcinoma. Positive gallium Ga-67 uptake in the absence of prior symptoms warrants follow-up as an indication of a potential disease state. Gallium Citrate Ga 67 Injection may be useful as an aid in detecting some acute inflammatory lesions.
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
It has been reported in the scientific literature that following intravenous injection, the highest tissue concentration of gallium Ga-67 - other than tumors and sites of infection - is the renal cortex. After the first day, the maximum concentration shifts to bone and lymph nodes and after the first week, to liver and spleen. Gallium Ga-67 is excreted relatively slowly from the body. The average whole body retention is 65 percent after seven days, with 26 percent having been excreted in the urine and 9 percent in the stools.
- Mechanism of action
Gallium Citrate Ga 67, with no carrier added, has been found to concentrate in certain viable primary and metastatic tumors as well as focal sites of infection. The body generally handles Ga3+ as though it were ferric iron (Fe-III), and thus the free isotope ion is bound (and concentrates) in areas of inflammation, such as an infection site, and also areas of rapid cell division. Ga-67 binds to transferrin, leukocyte lactoferrin, bacterial siderophores, inflammatory proteins, and cell-membranes in neutrophils, both living and dead. Lactoferrin is contained within leukocytes. Ga-67 may bind to lactoferrin and be transported to sites of inflammation, or binds to lactoferrin released during bacterial phagocytosis at infection sites (and remains due to binding with macrophage receptors). Ga-67 also attaches to the siderophore molecules of bacteria themselves, and for this reason can be used in leukopenic patients with bacterial infection (here it attaches directly to bacterial proteins, and leukocytes are not needed). Uptake is thought to be associated with a range of tumour properties including transferring receptors, anaerobic tumor metabolism and tumor perfusion and vascular permeability.
- Absorption
The body generally handles Ga3+ as though it were ferric iron (Fe-III). However, gallium can not be reduced in vivo. Therefore, ferric ion is easily reduced and interacts with protoporphyrin IX to form heme, gallium remains bound to iron-transport proteins and carrier molecules.
- Volume of distribution
Not Available
- Protein binding
Gallium binds to at least four iron-binding molecules: transferrin, lactoferrin, ferritin, and siderophores. Siderophores are compounds of low molecular weight that facilitate iron uptake by microorganisms.
- Metabolism
- Not Available
- Route of elimination
No urinary excretion; elimination primarily via fecal excretion.
- Half-life
78.26 hours
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- No interactions found.
Products
- Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.
- Active Moieties
Name Kind UNII CAS InChI Key Gallium cation Ga-67 ionic 99T03J52W0 Not Available CKHJYUSOUQDYEN-OIOBTWANSA-N - International/Other Brands
- Neoscan (Medi-Physics, Inc.)
- Brand Name Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Gallium Injection 2.0 mCi/1mL Intravenous Lantheus Medical Imaging, Inc. 1976-05-17 Not applicable US Gallium Citrate Ga-67 Injection, solution 2 mCi/1mL Intravenous Mallinckrodt 2008-02-21 2017-07-01 US
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as tricarboxylic acids and derivatives. These are carboxylic acids containing exactly three carboxyl groups.
- Kingdom
- Organic compounds
- Super Class
- Organic acids and derivatives
- Class
- Carboxylic acids and derivatives
- Sub Class
- Tricarboxylic acids and derivatives
- Direct Parent
- Tricarboxylic acids and derivatives
- Alternative Parents
- Tertiary alcohols / Carboxylic acid salts / Carboxylic acids / Organic salts / Organic oxides / Hydrocarbon derivatives / Carbonyl compounds
- Substituents
- Alcohol / Aliphatic acyclic compound / Carbonyl group / Carboxylic acid / Carboxylic acid salt / Hydrocarbon derivative / Organic oxide / Organic oxygen compound / Organic salt / Organooxygen compound
- Molecular Framework
- Aliphatic acyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Humans and other mammals
Chemical Identifiers
- UNII
- 4LJK511Z86
- CAS number
- 41183-64-6
- InChI Key
- YEEGWNXDUZONAA-RYDPDVNUSA-K
- InChI
- InChI=1S/C6H8O7.Ga/c7-3(8)1-6(13,5(11)12)2-4(9)10;/h13H,1-2H2,(H,7,8)(H,9,10)(H,11,12);/q;+3/p-3/i;1-3
- IUPAC Name
- (67Ga)gallium(3+) 2-hydroxypropane-1,2,3-tricarboxylate
- SMILES
- [67Ga+3].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O
References
- General References
- External Links
- PubChem Compound
- 65430
- PubChem Substance
- 347827795
- ChemSpider
- 58893
- 272758
- ChEBI
- 31645
- ChEMBL
- CHEMBL1200994
- Drugs.com
- Drugs.com Drug Page
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 1 Terminated Treatment Brain Neoplasm / Central Nervous System Neoplasm 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Bristol-Myers Squibb Co.
- Mallinckrodt Inc.
- Dosage Forms
Form Route Strength Injection Intravenous 74 MBq Injection, solution Intravenous Injection Intravenous 2.0 mCi/1mL Injection Intravenous 37 MBq Injection, solution Intravenous 2 mCi/1mL - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 3.21 mg/mL ALOGPS logP 1.06 ALOGPS logP -1.3 Chemaxon logS -2.1 ALOGPS pKa (Strongest Acidic) 3.05 Chemaxon pKa (Strongest Basic) -4.2 Chemaxon Physiological Charge -3 Chemaxon Hydrogen Acceptor Count 7 Chemaxon Hydrogen Donor Count 1 Chemaxon Polar Surface Area 140.62 Å2 Chemaxon Rotatable Bond Count 5 Chemaxon Refractivity 68.14 m3·mol-1 Chemaxon Polarizability 14.25 Å3 Chemaxon Number of Rings 0 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
Property Value Probability Human Intestinal Absorption - 0.7684 Blood Brain Barrier + 0.9683 Caco-2 permeable - 0.6826 P-glycoprotein substrate Non-substrate 0.7725 P-glycoprotein inhibitor I Non-inhibitor 0.953 P-glycoprotein inhibitor II Non-inhibitor 0.9204 Renal organic cation transporter Non-inhibitor 0.9563 CYP450 2C9 substrate Non-substrate 0.8503 CYP450 2D6 substrate Non-substrate 0.8955 CYP450 3A4 substrate Non-substrate 0.7068 CYP450 1A2 substrate Non-inhibitor 0.9115 CYP450 2C9 inhibitor Non-inhibitor 0.9313 CYP450 2D6 inhibitor Non-inhibitor 0.9365 CYP450 2C19 inhibitor Non-inhibitor 0.9252 CYP450 3A4 inhibitor Non-inhibitor 0.9071 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.9909 Ames test Non AMES toxic 0.8123 Carcinogenicity Non-carcinogens 0.622 Biodegradation Ready biodegradable 0.8965 Rat acute toxicity 1.8998 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.9909 hERG inhibition (predictor II) Non-inhibitor 0.9791
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS Not Available
Carriers
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- No
- Actions
- Binder
- General Function
- Transferrin receptor binding
- Specific Function
- Transferrins are iron binding transport proteins which can bind two Fe(3+) ions in association with the binding of an anion, usually bicarbonate. It is responsible for the transport of iron from si...
- Gene Name
- TF
- Uniprot ID
- P02787
- Uniprot Name
- Serotransferrin
- Molecular Weight
- 77063.195 Da
References
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- No
- Actions
- Binder
- General Function
- Serine-type endopeptidase activity
- Specific Function
- Transferrins are iron binding transport proteins which can bind two Fe(3+) ions in association with the binding of an anion, usually bicarbonate.Lactotransferrin is a major iron-binding and multifu...
- Gene Name
- LTF
- Uniprot ID
- P02788
- Uniprot Name
- Lactotransferrin
- Molecular Weight
- 78181.225 Da
References
- Hoffer P: Gallium: mechanisms. J Nucl Med. 1980 Mar;21(3):282-5. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- No
- Actions
- Binder
- General Function
- Iron ion binding
- Specific Function
- Stores iron in a soluble, non-toxic, readily available form. Important for iron homeostasis. Iron is taken up in the ferrous form and deposited as ferric hydroxides after oxidation. Also plays a ro...
- Gene Name
- FTL
- Uniprot ID
- P02792
- Uniprot Name
- Ferritin light chain
- Molecular Weight
- 20019.49 Da
References
- Hoffer P: Gallium: mechanisms. J Nucl Med. 1980 Mar;21(3):282-5. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- No
- Actions
- Binder
- General Function
- Iron ion binding
- Specific Function
- Stores iron in a soluble, non-toxic, readily available form. Important for iron homeostasis. Has ferroxidase activity. Iron is taken up in the ferrous form and deposited as ferric hydroxides after ...
- Gene Name
- FTH1
- Uniprot ID
- P02794
- Uniprot Name
- Ferritin heavy chain
- Molecular Weight
- 21225.47 Da
References
- Hoffer P: Gallium: mechanisms. J Nucl Med. 1980 Mar;21(3):282-5. [Article]
Drug created at September 14, 2010 16:21 / Updated at December 04, 2021 06:47